Skip to main content

Giving patients choice and control is the key to delivering global health equity

We’ve led the charge in patient-first clinical trials for over 20 years.

From developing hybrid trial methodology that blends site-based and decentralised clinical research elements with a new home-based health care provision model to the latest iteration of primarius patient, we create and develop products and services that push the boundaries of what is possible for clinical research and patient care.

There are always lots of exciting developments here at mdgroup. As some of our team return from speaking at another insightful DCT event in Boston, Massachusetts, this month, I was reminded why we keep pushing this industry forward: our commitment to achieving global health equity in our lifetime.

I found it interesting that of the 46 brilliant and engaging speakers at the event, only one of them, Jamie Tyrone, was at the conference to discuss her lived patient experience.

We understand and listen to patients across the business every single day. It’s our ‘why’ and the one common thread that ties all of our product and service developments together.

If you really listen to patients talk about their experiences of rare and serious diseases, their daily challenges, and how being involved in clinical trials gives them hope, what you hear is the key to delivering the efficacious outcomes we all want from clinical trials.

Choice and control

Simply put, we like having choices because it makes us feel in control.

Control is a natural human desire and gives us a feeling of order, stability, and safety. Developed as a concept in 1954 by Julian B. Rotter, the Locus of Control is the degree to which people feel control over the outcome of events in their lives. The greater the feeling, the better the mental well-being.

By giving patients choice and control, effectively giving them agency over their clinical trial experience, they become empowered and engaged. With engagement, retention follows, and with retention comes more efficacious trial outcomes.

Every product and service we have, and continue to develop, follows this simple and effective theory.

By listening to patients, understanding their need for agency, and giving them the platform, tools, and power to be partners in their care rather than the subjects of study, we will win the race to reach global health equity.

What do you think?

Join in the conversation over on LinkedIn or Twitter using the hashtag #mdtalk.

Need Help?
Hi! Please select an option